NICE has recommended broadening NHS use of Novartis' IL-17 inhibitor Cosentyx to include children aged six to 17 with severe plaque psoriasis. The cost-effectiveness agency says in draft guidance that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results